Hydrophobic Auristatin F Compounds for New Therapeutic Applications

The inventive concept expands the application of hydrophobic Auristatin F compounds to new therapeutic areas, including neurodegenerative diseases, inflammation, respiratory diseases, cancer biomarker detection, and cardiovascular diseases, by conjugating them to targeting moieties that specifically bind to disease-associated proteins or markers.

The original patent disclosed hydrophobic Auristatin F compounds and conjugates for treating cancer cells. However, the patent's scope was limited to oncology. The inventive concept addresses this limitation by exploring new therapeutic applications for these compounds, leveraging their unique properties to tackle complex diseases in diverse fields.

The inventive concept involves conjugating hydrophobic Auristatin F compounds to targeting moieties that specifically bind to disease-associated proteins or markers in various therapeutic areas. For instance, in neurodegenerative diseases, the conjugate can reduce protein aggregation and promote neuronal survival. In inflammation, the conjugate can target inflammatory markers, reducing inflammation and promoting tissue repair. Similarly, in respiratory diseases, the conjugate can target respiratory epithelial cell surface receptors, reducing inflammation and promoting lung function. In cancer biomarker detection, the conjugate can enable early detection and diagnosis. Finally, in cardiovascular diseases, the conjugate can target cardiovascular disease-associated proteins, reducing cardiovascular risk and promoting cardiovascular health.

The inventive concept's novelty lies in the unexpected application of hydrophobic Auristatin F compounds to new therapeutic areas, exploiting their unique properties to address complex diseases. The inventive step resides in the specific design of the conjugates, which enables the compounds to target disease-associated proteins or markers, thereby achieving therapeutic efficacy in these new areas.

Alternative embodiments of the inventive concept could involve varying the targeting moieties, the linker chemistry, or the Auristatin F compound itself to optimize performance in different therapeutic areas. Additionally, the conjugates could be formulated for different routes of administration, such as oral, injectable, or topical, to enhance patient compliance and convenience.

The inventive concept has significant commercial potential in various therapeutic areas, including neurodegenerative diseases, inflammation, respiratory diseases, cancer biomarker detection, and cardiovascular diseases. The market for these applications is substantial, with growing demand for innovative treatments that can address complex diseases. The inventive concept's ability to provide targeted therapies with improved efficacy and safety profiles positions it for significant market share and revenue growth.